Although the underlying mechanisms of drug combination effectiveness need further investigation, the present study highlighted that trabectedin and, to a higher extent, the combined treatment hindered the DDR response pathway in the tested gynecological cancer models and offset resistance mechanisms elicited by β-ARs activation, promoting apoptosis. This evidence concerns the gene CTBP1 and female reproductive organ cancer.